Paul J Sabbatini

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up
    Richard R Barakat
    Gynecology Service, Department of Surgery, Gynecology Disease Management Team, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:694-8. 2002
  2. doi request reprint Platinum resistance and impaired survival in patients with advanced primary peritoneal carcinoma: matched-case comparison with patients with epithelial ovarian carcinoma
    Eric L Eisenhauer
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Obstet Gynecol 198:213.e1-7. 2008
  3. ncbi request reprint Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer
    Paul J Sabbatini
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:4170-7. 2007
  4. ncbi request reprint Early CA-125 fluctuations in patients with recurrent ovarian cancer receiving chemotherapy
    P Sabbatini
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Int J Gynecol Cancer 17:589-94. 2007
  5. ncbi request reprint CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy
    Margrit M Juretzka
    Gynecology Oncology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 104:176-80. 2007
  6. doi request reprint Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study
    Paul Sabbatini
    Kliniken Essen Mitte, Germany
    J Clin Oncol 31:1554-61. 2013
  7. doi request reprint Consolidation therapy in ovarian cancer: a clinical update
    Paul Sabbatini
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    Int J Gynecol Cancer 19:S35-9. 2009
  8. ncbi request reprint Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
    Paul Sabbatini
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 22:4523-31. 2004
  9. doi request reprint Consolidation strategies in ovarian cancer: observations for future clinical trials
    Paul Sabbatini
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 116:66-71. 2010
  10. ncbi request reprint The relationship between anemia and quality of life in cancer patients
    P Sabbatini
    Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncologist 5:19-23. 2000

Research Grants

  1. Ovarian Cancer: Strategies for consolidation
    Paul Sabbatini; Fiscal Year: 2006

Detail Information

Publications53

  1. ncbi request reprint Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up
    Richard R Barakat
    Gynecology Service, Department of Surgery, Gynecology Disease Management Team, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:694-8. 2002
    ..To determine long-term survival and predictors of recurrence in a retrospective cohort of patients with epithelial ovarian cancer treated with intraperitoneal (IP) chemotherapy...
  2. doi request reprint Platinum resistance and impaired survival in patients with advanced primary peritoneal carcinoma: matched-case comparison with patients with epithelial ovarian carcinoma
    Eric L Eisenhauer
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Obstet Gynecol 198:213.e1-7. 2008
    ..The objective of the study was to compare chemotherapy response and survival of patients with advanced primary peritoneal carcinoma (PPC) vs those with epithelial ovarian carcinoma (EOC)...
  3. ncbi request reprint Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer
    Paul J Sabbatini
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:4170-7. 2007
    ....
  4. ncbi request reprint Early CA-125 fluctuations in patients with recurrent ovarian cancer receiving chemotherapy
    P Sabbatini
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Int J Gynecol Cancer 17:589-94. 2007
    ..Discontinuation of therapy solely on the basis of early CA-125 increase (precycle 3), particularly with liposomal doxorubicin chemotherapy, may exclude some patients who will benefit from continued therapy...
  5. ncbi request reprint CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy
    Margrit M Juretzka
    Gynecology Oncology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 104:176-80. 2007
    ..A secondary objective was to assess the relationship of CA125 level to PFS...
  6. doi request reprint Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study
    Paul Sabbatini
    Kliniken Essen Mitte, Germany
    J Clin Oncol 31:1554-61. 2013
    ..To determine whether abagovomab maintenance therapy prolongs recurrence-free (RFS) and overall survival (OS) in patients with ovarian cancer in first clinical remission...
  7. doi request reprint Consolidation therapy in ovarian cancer: a clinical update
    Paul Sabbatini
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    Int J Gynecol Cancer 19:S35-9. 2009
    ..Many relapse, unfortunately, but some can return to remission after additional treatment. Outcomes can be improved by applying effective consolidation or maintenance approaches to patients in a complete primary or subsequent remission...
  8. ncbi request reprint Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
    Paul Sabbatini
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 22:4523-31. 2004
    ..To evaluate the safety and efficacy of CT-2103, a novel conjugate of paclitaxel and poly-L-glutamic acid, in heavily pretreated patients with recurrent ovarian, fallopian tube, or peritoneal cancer...
  9. doi request reprint Consolidation strategies in ovarian cancer: observations for future clinical trials
    Paul Sabbatini
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 116:66-71. 2010
    ..CONCLUSION.: Preliminary benchmarks for efficacy endpoints are suggested for future consolidation trials of patients in cCR. However, the suggested strategies will require validation in randomized trials and larger data sets...
  10. ncbi request reprint The relationship between anemia and quality of life in cancer patients
    P Sabbatini
    Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncologist 5:19-23. 2000
    ..Additional studies are evaluating the optimal hemoglobin levels for the greatest incremental improvement in QOL...
  11. doi request reprint A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study
    Paul Sabbatini
    Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Center, New York, NY 10021, USA
    Gynecol Oncol 111:455-60. 2008
    ..To estimate the anti-tumor activity and toxicity of paclitaxel poliglumex (PPX) in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (EOC) in second or third line treatment...
  12. ncbi request reprint Immunologic approaches to ovarian cancer treatment
    Paul Sabbatini
    Medical Gynecologic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    J Clin Oncol 25:2884-93. 2007
    ..Basic principles generic to all these immunotherapeutic approaches will be discussed in the hopes of yielding the most promising results as the field continues to evolve...
  13. ncbi request reprint Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial
    Paul Sabbatini
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 10:2962-7. 2004
    ..p. cisplatin with i.p. gemcitabine in patients with persistent disease at second-look assessment, the toxicity of this regimen, and the time to treatment failure and overall survival...
  14. doi request reprint Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer
    Joyce N Barlin
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 125:621-4. 2012
    ..We sought to evaluate the PFS, OS, toxicity, and completion rate of a modified outpatient IP regimen...
  15. doi request reprint The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment
    Roisin O'Cearbhaill
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 116:326-31. 2010
    ....
  16. doi request reprint Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma
    John P Diaz
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 116:335-9. 2010
    ..The objective of this study was to examine the incidence and management of bevacizumab-associated gastrointestinal (GI) perforations in patients with recurrent ovarian carcinoma...
  17. doi request reprint A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer
    Jason Konner
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 110:140-5. 2008
    ..Determine the safety and efficacy of cetuximab plus paclitaxel and carboplatin as initial treatment of stage III/IV ovarian cancer...
  18. doi request reprint Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer
    Oliver Zivanovic
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    Gynecol Oncol 115:209-14. 2009
    ..To analyze whether serum CA-125 response to cytoreductive surgery before initiation of postoperative chemotherapy is associated with progression-free survival (PFS) in patients with stage IIIC ovarian carcinoma...
  19. pmc Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer
    Jason A Konner
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 29:4662-8. 2011
    ..Bevacizumab prolongs progression-free survival (PFS) when included in first-line IV chemotherapy. In this study, the safety and feasibility of adding bevacizumab to a first-line IP regimen were assessed...
  20. doi request reprint Incidence of intestinal obstruction following intraperitoneal chemotherapy for ovarian tubal and peritoneal malignancies
    Siobhan M Kehoe
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 113:228-32. 2009
    ..To report the incidence of intestinal obstruction after intraperitoneal chemotherapy (IP) in women with ovarian, tubal, or peritoneal malignancies, and determine the frequency of malignant versus adhesion-related obstruction...
  21. ncbi request reprint Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial
    Martee L Hensley
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:2824-31. 2002
    ..Few chemotherapy agents are active in leiomyosarcoma (LMS), particularly LMS that has progressed after doxorubicin treatment. We sought to determine the response to gemcitabine plus docetaxel among patients with LMS...
  22. doi request reprint Prognostic factors for patients with stage IV epithelial ovarian cancer receiving intraperitoneal chemotherapy after second-look assessment: results of long-term follow-up
    Oliver Zivanovic
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 112:2690-7. 2008
    ..The aim was to determine the long-term outcome for patients with FIGO stage IV epithelial ovarian carcinoma (EOC) treated with intraperitoneal (IP) chemotherapy after second-look assessment...
  23. doi request reprint Early postoperative CT as a prognostic biomarker in patients with advanced ovarian, tubal, and primary peritoneal cancer deemed optimally debulked at primary cytoreductive surgery
    Yulia Lakhman
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    AJR Am J Roentgenol 198:1453-9. 2012
    ..Lesions larger than 1 cm with a CT score of 4 or 5 were considered suboptimally debulked residual disease...
  24. ncbi request reprint Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy
    Don S Dizon
    Developmental Chemotherapy Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Gynecol Oncol 84:378-82. 2002
    ..One case is presented in which a heavily pretreated patient suffered a severe anaphylactic reaction, which was refractory to standard resuscitative measures and resulted in her death...
  25. ncbi request reprint Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience
    Don S Dizon
    Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY New York 10021, USA
    Gynecol Oncol 91:584-90. 2003
    ..In addition, we sought to compare these results to the outcomes in women who received carboplatin and paclitaxel (C + T) at first relapse...
  26. ncbi request reprint Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study
    Mika A Sovak
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 103:451-7. 2006
    ..To determine overall survival and progression-free survival among patients with high-risk, stage III and IV endometrial cancer who receive paclitaxel and carboplatin (TC) after complete tumor resection...
  27. ncbi request reprint Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer
    Don S Dizon
    Department of Medicine, Division of Developmental Chemotherapy, and Department of Gynecologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 20:1238-47. 2002
    ..We sought to determine the outcomes for patients with EOC treated with carboplatin and paclitaxel at the time of first recurrence. In addition, we sought to define a new paradigm for disease transition in patients with EOC...
  28. doi request reprint Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study
    Martee L Hensley
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Gynecol Oncol 112:563-7. 2009
    ..We sought to determine whether adjuvant gemcitabine-docetaxel would yield a 2-year progression-free survival of at least 50% in this leiomyosarcoma population...
  29. pmc Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study
    Noah D Kauff
    Clinical Genetics and Gynecology Services, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 192, New York, NY 10021, USA
    J Clin Oncol 26:1331-7. 2008
    ....
  30. doi request reprint Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission
    Catherine S M Diefenbach
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 14:2740-8. 2008
    ..In this study, we describe the effects of vaccination with the HLA-A*0201-restricted NY-ESO-1b peptide on patients with epithelial ovarian cancer in high-risk first remission...
  31. doi request reprint Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study
    Jason A Konner
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 16:5288-95. 2010
    ..This phase I, dose-escalation study was conducted to determine the safety of weekly i.v. farletuzumab and establish the maximum tolerated dose (MTD)...
  32. doi request reprint Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors
    William P Tew
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 16:358-66. 2010
    ..To determine the maximum tolerated dose or maximal administered dose and pharmacokinetic and safety profiles of s.c. administered vascular endothelial growth factor Trap (aflibercept), a novel antiangiogenic agent...
  33. ncbi request reprint Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors
    Jakob Dupont
    Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 22:3366-74. 2004
    ..To determine maximum tolerated dose, pharmacokinetics (PK), and safety of Ro 31-7453, a novel, oral cell-cycle inhibitor...
  34. doi request reprint A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer
    Martee L Hensley
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Clin Cancer Res 14:6310-6. 2008
    ..To determine the maximally tolerated dose (MTD) of biweekly pemetrexed with gemcitabine plus B(12) and folate supplementation in patients with advanced solid tumors and ovarian cancer...
  35. ncbi request reprint Early detection and prognosis of ovarian cancer using serum YKL-40
    Jakob Dupont
    Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Howard 905, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 22:3330-9. 2004
    ..YKL-40 is a secreted glycoprotein (chitinase family). We compared YKL-40 with two ovarian cancer serum markers, CA125 and CA15-3, for the detection of early-stage ovarian cancer...
  36. ncbi request reprint Patient online self-reporting of toxicity symptoms during chemotherapy
    Ethan Basch
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 E 63rd St, New York, NY 10021, USA
    J Clin Oncol 23:3552-61. 2005
    ..Currently, clinicians collect symptom information via complex and often inefficient mechanisms, but there is growing interest in collecting outcome information directly from patients...
  37. ncbi request reprint Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning
    Martee L Hensley
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 102:270-7. 2006
    ....
  38. ncbi request reprint New agents and new formulations for the treatment of ovarian cancer
    Paul Sabbatini
    Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, USA
    Clin Adv Hematol Oncol 3:840-2. 2005
  39. ncbi request reprint Retroperitoneal nodal metastasis in primary and recurrent granulosa cell tumors of the ovary
    Nadeem R Abu-Rustum
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Room C 1096, New York, NY 10021, USA
    Gynecol Oncol 103:31-4. 2006
    ..To describe the incidence of retroperitoneal pelvic or paraaortic lymph node metastasis in patients with primary and recurrent ovarian granulosa cell tumors...
  40. ncbi request reprint Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer
    Monica Prasad
    Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 93:223-8. 2004
    ..We report overall costs and treatment outcomes associated with topotecan or gemcitabine administration in platinum- and paclitaxel-resistant EOC patients...
  41. ncbi request reprint Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy
    Mario M Leitao
    Gynecology Service, Department of Surgery, Gynecology Disease Management Team, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 91:123-9. 2003
    ..The objective was to determine the response rate to platinum retreatment of "platinum-resistant" ovarian cancer after intervening nonplatinum therapy...
  42. ncbi request reprint Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas
    Carol Aghajanian
    Developmental Chemotherapy Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:1082-8. 2007
    ..Dosing schedules of 40 mg/m2 and 50 mg/m2 over 3 hours were also evaluated...
  43. ncbi request reprint A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors
    Martee L Hensley
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Invest New Drugs 25:335-41. 2007
    ..Attempts to increase the dose of BMS-247550 by decreasing the gemcitabine dose did not sufficiently ameliorate myelosuppression. Stable disease was observed in some patients with prior taxane exposure...
  44. ncbi request reprint A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies
    Carol Aghajanian
    The Developmental Chemotherapy Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:2505-11. 2002
    ..v. bolus for 2 weeks, followed by a 1-week recovery period in patients with advanced solid tumor malignancies...
  45. ncbi request reprint Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach
    Dennis S Chi
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 94:650-4. 2004
    ....
  46. ncbi request reprint Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma
    Mario M Leitao
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer 101:1455-62. 2004
    ..The authors also sought to assess the prognostic value of ER, PR, and AR expression in LMS...
  47. ncbi request reprint The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer
    Oliver Zivanovic
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave New York, NY 10021, USA
    Gynecol Oncol 108:287-92. 2008
    ..To analyze the impact of bulky upper abdominal disease (UAD) cephalad to the greater omentum on surgical outcomes for patients with stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal carcinoma...
  48. ncbi request reprint Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer
    Paul Sabbatini
    Memorial Sloan Kettering Cancer Center, New York, New York, Franklin Square Hospital, Baltimore, MD, USA, and University of Marburg, Germany
    Clin Cancer Res 12:5503-10. 2006
    ....
  49. ncbi request reprint Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer
    Catherine S M Diefenbach
    Gynecologic Medical Oncology, Department of Medicine, Howard 903, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 104:435-42. 2007
    ..In this study, we examined the frequency of serum elevation as well as the diagnostic and prognostic significance of this serum marker in endometrial cancer...
  50. ncbi request reprint A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission
    Douglas Levine
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 110:2448-56. 2007
    ..The current study was conducted to determine the effect of goserelin and bicalutamide on progression-free survival (PFS) in patients with epithelial ovarian cancer who were in second or greater complete disease remission...
  51. ncbi request reprint Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature
    Tiffany A Traina
    Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 95:235-41. 2004
    ..We have included a review of the literature of weekly topotecan in the treatment of patients with gynecologic cancer...
  52. ncbi request reprint Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma
    Bhavana Pothuri
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 96:330-4. 2005
    ..To analyze the feasibility of using percutaneous endoscopic gastrostomy (PEG) tube placement in ovarian cancer patients with malignant bowel obstruction and to analyze the outcome of these patients...
  53. ncbi request reprint Major hepatectomy at interval debulking for stage IV ovarian carcinoma: a case report
    Dennis S Chi
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 87:138-42. 2002
    ..Previous studies have reported the results of hepatic resection for metastatic ovarian cancer at the time of primary cytoreductive surgery and at the time of recurrence...

Research Grants1

  1. Ovarian Cancer: Strategies for consolidation
    Paul Sabbatini; Fiscal Year: 2006
    ..Promising strategies will be moved to patients in primary remission (Specific Aim 1) with a current median time to treatment failure of 18-21 months...